ArticleThe European journal of health economics : HEPAC : health economics in prevention and care2026
Translating the EORTC CAT core and the QLQ-C30 to the EQ-5D-5L in patients with metastatic breast cancer: A comparison of direct and indirect mapping algorithms.
Article in The European journal of health economics : HEPAC : health economics in prevention and care, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Mapping EORTC-QLQ-C30 scores to EQ-5D-5L utility values for gynecological cancer survivors in follow-up care.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2026Article
- Updated algorithms for direct and indirect mapping of WHOQOL-BREF to EQ-5D-5L utility scores using data from a multi-provincial Thai general population sample.Health and quality of life outcomes · 2026Article
- The Multidimensional Burden of COPD in China: A Propensity Score-Matched Comparison with Other Prevalent Non-Communicable Diseases.International journal of chronic obstructive pulmonary disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo enable the use of different non-preference-based patient-reported outcome measures to derive utility values for health economic evaluations in oncological trials, this study developed direct and indirect mapping algorithms for estimating the EQ-5D-5L utility index via the German value set from the EORTC CAT Core and the QLQ-C30 in metastatic breast cancer patients.
methodsWe included 1,839 observations from 878 patients with metastatic breast cancer from the PRO B study. We compared direct mapping algorithms, including adjusted limited dependent variable mixture models (ALDVMM), Tobit regression, ordinal least squares regression, and adjusted beta regression, while indirect mapping employed a generalized ordered logit model. Visualization was used to assess model performance across the entire distribution, while quantitative evaluation was performed using mean absolute error (MAE), root mean squared error (RMSE), and mean prediction bias.
resultsAmong the direct algorithms, adjusted beta regression demonstrated the best performance. It had the lowest MAE of 0.07-0.08 and RMSE of 0.11-0.13, a mean prediction bias of -0.004, close to zero. The indirect mapping model also performed well, with a mean prediction bias of 0.04 and MAE of 0.07, showing performance comparable to the preferred direct mapping algorithm for both the EORTC CAT Core and the QLQ-C30.
conclusionsThis study developed and validated robust direct and indirect algorithms for estimating the EQ-5D-5L utility index from the EORTC CAT Core and the QLQ-C30 based on the German tariff. In particular, using this indirect mapping algorithm, the EORTC CAT Core and QLQ-C30 can be translated into quality-adjusted life-years, facilitating health economic evaluations across different country tariffs.
trial registrationDRKS (German Clinical Trials Register) DRKS00024015. Registered on 15 February 2021, https//drks.de/search/de/trial/DRKS00024015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.